

## Clinical guideline updates are available on anthem.com

Published: Oct 1, 2018 - **Policy Updates** / Medical Policy & Clinical Guidelines

The following new and revised medical policies were endorsed at the July 26, 2018 Medical Policy & Technology Assessment Committee (MPTAC) meeting. These, and all Anthem medical policies, are available at [anthem.com/provider](http://anthem.com/provider) > scroll down and select 'Find Resources for [state]' > [CT Medical Policies and Clinical UM Guidelines](#) [ME Medical Policies and Clinical UM Guidelines](#) [NH Medical Policies and Clinical UM Guidelines](#).

If you do not have access to the internet, you may request a hard copy of any updated policy by contacting the [CT Provider Call Center](#) [ME Provider Call Center](#) [NH Provider Call Center](#).

### **Revised clinical guidelines effective August 2, 2018**

(The following guidelines were revised to expand medical necessity indications or criteria.)

CG-SURG-24 - Functional Endoscopic Sinus Surgery (FESS)  
CG-SURG-73 - Balloon Sinus Ostial Dilation

### **Revised clinical guidelines effective August 29, 2018**

(The following guidelines were revised to expand medical necessity indications or criteria.)

CG-DRUG-09 - Immune Globulin (Ig) Therapy  
CG-DRUG-65 - Tumor Necrosis Factor Antagonists  
CG-DRUG-68 - Bevacizumab (Avastin®) for Non-Ophthalmologic Indications  
CG-DRUG-73 - Denosumab (Prolia®, Xgeva®)  
CG-DRUG-81 - Tocilizumab (Actemra®)  
CG-GENE-03 - BRAF Mutation Analysis

### **Revised clinical guidelines effective August 29, 2018**

(The following guidelines were reviewed and had no significant changes to the position or criteria.)

CG-DME-07 - Augmentative and Alternative Communication (AAC) Devices/Speech Generating Devices (SGD)  
CG-DRUG-05 - Recombinant Erythropoietin Products  
CG-DRUG-11 - Infertility Drugs  
CG-DRUG-24 - Repository Corticotropin Injection (H.P. Acthar® Gel)  
CG-DRUG-47 - Level of Care: Specialty Pharmaceuticals  
CG-DRUG-56 - Galsulfase (Naglazyme®)  
CG-DRUG-69 - Ustekinumab (Stelara®)  
CG-DRUG-72 - Pertuzumab (Perjeta®)  
CG-DRUG-90 - Intravitreal Treatment for Retinal Vascular Conditions

CG-GENE-02 - Analysis of KRAS Status  
CG-GENE-04 - Molecular Marker Evaluation of Thyroid Nodules  
CG-MED-26 - Neonatal Levels of Care  
CG-REHAB-08 - Private Duty Nursing in the Home Setting  
CG-SURG-05 - Maze Procedure  
CG-SURG-08 - Sacral Nerve Stimulation as a Treatment of Neurogenic Bladder Secondary to Spinal Cord Injury  
CG-SURG-12 - Penile Prosthesis Implantation  
CG-SURG-33 - Lumbar Fusion and Lumbar Total Disc Arthroplasty  
CG-SURG-38 - Lumbar Laminectomy, Hemi-Laminectomy, Laminotomy and/or Discectomy  
CG-SURG-42 - Cervical Fusion  
CG-SURG-43 - Knee Arthroscopy  
CG-SURG-44 - Coronary Angiography in the Outpatient Setting  
CG-SURG-47 - Surgical Interventions for Scoliosis and Spinal Deformity  
CG-SURG-48 - Elective Percutaneous Coronary Interventions (PCI)  
CG-SURG-53 - Elective Total Hip Arthroplasty  
CG-SURG-54 - Elective Total Knee Arthroplasty  
CG-SURG-60 - Cervical Total Disc Arthroplasty  
CG-SURG-65 - Recombinant Human Bone Morphogenetic Protein  
CG-SURG-66 - Implanted (Epidural and Subcutaneous) Spinal Cord Stimulators (SCS)  
CG-SURG-67 - Treatment of Osteochondral Defects  
CG-SURG-68 - Surgical Treatment of Femoroacetabular Impingement Syndrome  
CG-SURG-69 - Meniscal Allograft Transplantation of the Knee  
CG-THER-RAD-03 - Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy

### **New and adopted clinical guidelines effective September 20, 2018**

(The following guidelines were previously medical policies and have been adopted as clinical guidelines. No significant changes were made.)

CG-DME-45 - Ultrasound Bone Growth Stimulation  
CG-DRUG-103 - Botulinum Toxin  
CG-DRUG-104 - Omalizumab (Xolair®)  
CG-DRUG-105 - Abatacept (Orencia®)  
CG-DRUG-106 - Brentuximab Vedotin (Adcetris®)  
CG-DRUG-107 - Pharmacotherapy for Hereditary Angioedema  
CG-DRUG-108 - Enteral Carbidopa and Levodopa Intestinal Gel Suspension  
CG-DRUG-109 - Asfotase Alfa (Strensiq™)  
CG-DRUG-110 - Naltrexone Implantable Pellets  
CG-DRUG-111 - Sebelipase alfa (KANUMA™)  
CG-DRUG-112 - Abaloparatide (Tymlos™) Injection  
CG-MED-73 - Hyperbaric Oxygen Therapy (Systemic/Topical)  
CG-MED-74 - Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry  
CG-MED-75 - Medical and Other Non-Behavioral Health Related Treatments for Autism Spectrum Disorders and Rett Syndrome  
CG-MED-76 - Magnetic Source Imaging and Magnetoencephalography  
CG-MED-77 - SPECT/CT Fusion Imaging  
CG-REHAB-11 - Cognitive Rehabilitation  
CG-SURG-81 - Cochlear Implants and Auditory Brainstem Implants  
CG-SURG-82 - Bone-Anchored and Bone Conduction Hearing Aids

CG-SURG-84 - Mandibular/ Maxillary (Orthognathic) Surgery  
CG-SURG-87 - Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring  
CG-SURG-88 - Mastectomy for Gynecomastia  
CG-SURG-89 - Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia  
CG-TRANS-03 - Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation

**Archived clinical guidelines effective October 1, 2018**

(The following guidelines were archived.)

CG-SURG-83 - Bariatric Surgery and other Treatments for Clinically Severe Obesity  
CG-SURG-85 - Hip Resurfacing  
CG-SURG-86 - Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection

**Revised clinical guideline effective January 1, 2019**

(The following guideline below might result in services that were previously covered now being considered not medically necessary.)

CG-DRUG-65 - Tumor Necrosis Factor Antagonists

**Archived clinical guidelines effective January 1, 2019. These guidelines are now AIM guidelines.**

CG-SURG-33 - Lumbar Fusion and Lumbar Total Disc Arthroplasty  
CG-SURG-38 - Lumbar Laminectomy, Hemi-Laminectomy, Laminotomy and/or Discectomy  
CG-SURG-42 - Cervical Fusion  
CG-SURG-43 - Knee Arthroscopy  
CG-SURG-44 - Coronary Angiography in the Outpatient Setting  
CG-SURG-47 - Surgical Interventions for Scoliosis and Spinal Deformity  
CG-SURG-48 - Elective Percutaneous Coronary Interventions (PCI)  
CG-SURG-53 - Elective Total Hip Arthroplasty  
CG-SURG-54 - Elective Total Knee Arthroplasty  
CG-SURG-60 - Cervical Total Disc Arthroplasty  
CG-SURG-65 - Recombinant Human Bone Morphogenetic Protein  
CG-SURG-66 - Implanted (Epidural and Subcutaneous) Spinal Cord Stimulators (SCS)  
CG-SURG-67 - Treatment of Osteochondral Defects  
CG-SURG-68 - Surgical Treatment of Femoroacetabular Impingement Syndrome  
CG-SURG-69 - Meniscal Allograft Transplantation of the Knee

**New and adopted clinical guidelines effective January 1, 2019**

(The following guidelines were previously unadopted and have now been adopted. No significant changes were made.)

CG-DME-09 - Continuous Local Delivery of Analgesia to Operative Sites using and Elastomeric Infusion Pump during the Post-operative Period  
CG-DME-13 - Lower Limb Prosthesis  
CG-DME-21 - External Infusion Pumps for the Administration of Drugs in the Home or Residential Care Settings

CG-OR-PR-04 - Cranial Remodeling Bands and Helmets (Cranial Orthotics)  
CG- REHAB-02 - Outpatient Cardiac Rehabilitation  
CG-DRUG-33 - Palonosetron  
CG-DRUG-40 - Bortezomib (Velcade®)  
CG-DRUG-44 - Pegloticase (Krystexxa®)  
CG-DRUG-52 - Temsirolimus (Torisel®)  
CG-DRUG-60 - Gonadotropin Releasing Hormone Analogs for Oncologic Indications

**URL:** <https://providernews.anthem.com/connecticut/article/clinical-guideline-updates-are-available-on-anthemcom-3>

**Featured In:**

October 2018 Anthem Connecticut Provider Newsletter

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

---